Changes to Sub-Funds

Summary by AI ^BETAClose X

JPMorgan ETFs (Ireland) ICAV has announced an update to the supplements for certain Sub-Funds, effective February 16, 2026, which will modify their exclusion policies. Specifically, the 10% revenue threshold exclusion for conventional weapons will be removed, and the current full exclusion for nuclear weapons will be amended to permit investment in issuers supporting nuclear weapons programs for states within the Treaty on the Non-Proliferation of Nuclear Weapons. Shareholders can view the full document detailing these changes and available options via a provided URL.

Disclaimer*

JPMorgan ETFs (Ireland) ICAV

16 January 2026

JPMorgan ETFs (Ireland) ICAV

JPMorgan ETFs (Ireland) - Update to Supplements: Shareholder Notice - effective from 16 February 2026

This is to notify you that the supplements for certain Sub-Funds will be updated, with effect from 16 February 2026, to reflect changes to their exclusion policies as follows:

- remove the 10% revenue threshold exclusion relating to conventional weapons

- amend the current full exclusion relating to nuclear weapons to allow for investment in issuers who support nuclear weapons programmes to states within the Treaty on the Non-Proliferation of Nuclear Weapons, commonly known as the Non-Proliferation Treaty or ''NPT''

To view the full document including the options available to Shareholders, please paste the following URL into the address bar of your browser.

https://am.jpmorgan.com/content/dam/jpm-am-aem/emea/regional/en/supplemental/notice-to-shareholders/jpm57249-shareholder-mailing-etf-inv-policy-update-en.pdf

Enquiries:

JPMorgan

David Brigstocke

07830 316102

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END